Upstream Bio's Upcoming Investor Conferences: What to Expect
Upcoming Investor Conferences for Upstream Bio
In an active effort to engage with investors and stakeholders, Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, has announced its participation in several notable investor conferences this November. Rand Sutherland, MD, the Chief Executive Officer of Upstream Bio, will represent the company at these informative gatherings, shedding light on the advancements being made in their therapeutic applications.
Conferences Schedule
These conferences serve as a platform for Upstream Bio to connect with potential investors and share exciting developments about their innovations. Here are the conferences where Upstream Bio will be presenting:
Truist Securities BioPharma Symposium
This symposium will take place on Thursday, November 6, 2025, in New York. Dr. Sutherland is scheduled to participate in a panel starting at 8:10 a.m. ET, offering insights into the company’s direction and progress.
Stifel 2025 Healthcare Conference
On Tuesday, November 11, 2025, Dr. Sutherland will give a presentation at the prestigious Stifel Healthcare Conference, commencing at 9:20 a.m. ET, where he will delve into Upstream Bio’s key projects and their impact on the treatment landscape.
TD Cowen Immunology and Inflammation Summit
Following these events, on Wednesday, November 12, 2025, Upstream Bio will also participate in the TD Cowen Immunology and Inflammation Summit, hosting a fireside chat at 10:30 a.m. ET. This is another opportunity to discuss the company’s innovative approaches and scientific advancements in the field of therapy for inflammatory diseases.
Access to Presentations
For those unable to attend these conferences in person, live webcasts of the Stifel and Cowen presentations will be accessible through the Events tab on Upstream Bio’s website on the day of each event. Additionally, a replay of these webcasts will be made available, ensuring that interested parties can stay updated on Upstream Bio’s developments.
About Upstream Bio
Upstream Bio is committed to addressing the unmet needs of individuals suffering from inflammatory diseases, with a particular emphasis on severe respiratory disorders. One of their key products in development is verekitug. This drug is the only known antagonist currently in clinical development targeting the thymic stromal lymphopoietin (TSLP) receptor, which plays a significant role in mediating inflammatory responses linked to many immune-mediated diseases.
Upstream Bio is engaged in multiple Phase 2 trials of verekitug for conditions such as chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). The dedicated team at Upstream Bio is focused on maximizing the potential of verekitug to meet the critical healthcare needs of patients who struggle with existing treatment options.
Contact Information
For further inquiries or more information about Upstream Bio, you can reach out to:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
Email: ir@upstreambio.com
Frequently Asked Questions
What is Upstream Bio's primary focus?
Upstream Bio focuses on developing treatments for inflammatory diseases, specifically targeting severe respiratory disorders.
When are the upcoming conferences Upstream Bio will attend?
Upstream Bio will attend the Truist Securities BioPharma Symposium on November 6, Stifel 2025 Healthcare Conference on November 11, and TD Cowen Immunology and Inflammation Summit on November 12.
What is verekitug?
Verekitug is a monoclonal antibody being developed by Upstream Bio, targeting the receptor for TSLP, which is involved in inflammatory responses.
Will the presentations be available to the public?
Yes, live webcasts of the presentations will be available on Upstream Bio’s website, along with replay options afterward.
Who can I contact for media inquiries regarding Upstream Bio?
You can contact Meggan Buckwell, the Director of Corporate Communications and Investor Relations, through the provided email address.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
